Literature DB >> 35505018

An Orthotopic Murine Model of Peritoneal Carcinomatosis of Ovarian Origin for Intraoperative PDT.

Thierry Michy1,2, Claire Bernard1,2, Jean-Luc Coll1, Véronique Josserand3.   

Abstract

Advanced ovarian cancer is the most serious among gynecological malignancies and is associated with 35% five-year overall survival. Surgery is the first therapeutic indication, and the absence of remaining macroscopic lesions is the most important prognostic factor. However, tumor dissemination over the whole abdominal cavity largely contributes to the difficulty of complete surgical resection. Consequently, any therapeutic approach that may complete surgical resection should improve patient survival. Considering that some sites are not suitable for surgery because of their close location to vital organs, intraoperative photodynamic therapy (ioPDT) appears to be a complementary therapeutic approach to surgery to obtain the lowest residual disease.Relevant in vivo cancer models that closely resemble human ovarian cancer are essential for preclinical research of alternative antitumor therapeutic strategies. Thus, we propose a comprehensive protocol to set up an orthotopic ovarian xenograft in mice leading to peritoneal carcinomatosis that could be harnessed for antitumor therapeutic application and evaluation.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bioluminescence imaging; Intraoperative Photodynamic Therapy; Murine model; Orthotopic implantation; Ovarian peritoneal carcinomatosis

Mesh:

Substances:

Year:  2022        PMID: 35505018     DOI: 10.1007/978-1-0716-2099-1_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  22 in total

Review 1.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

2.  A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study.

Authors:  Anna Fagotti; Gabriella Ferrandina; Francesco Fanfani; Alfredo Ercoli; Domenica Lorusso; Marco Rossi; Giovanni Scambia
Journal:  Ann Surg Oncol       Date:  2006-06-21       Impact factor: 5.344

3.  Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.

Authors:  S M Eisenkop; R L Friedman; H J Wang
Journal:  Gynecol Oncol       Date:  1998-05       Impact factor: 5.482

4.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Authors:  Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

5.  Maximal cytoreductive effort in epithelial ovarian cancer surgery.

Authors:  Karin K Shih; Dennis S Chi
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

6.  External validation of a laparoscopic-based score to evaluate resectability for patients with advanced ovarian cancer undergoing interval debulking surgery.

Authors:  E Chereau; V Lavoue; M Ballester; C Coutant; F Selle; A Cortez; E Daraï; J Leveque; R Rouzier
Journal:  Anticancer Res       Date:  2011-12       Impact factor: 2.480

7.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

8.  Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer.

Authors:  Jo Marie Tran Janco; Gretchen Glaser; Bohyun Kim; Michaela E McGree; Amy L Weaver; William A Cliby; Sean C Dowdy; Jamie N Bakkum-Gamez
Journal:  Gynecol Oncol       Date:  2015-04-22       Impact factor: 5.482

9.  Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study.

Authors:  Scott M Eisenkop; Nick M Spirtos; Richard L Friedman; Wei-Chien Michael Lin; Albert L Pisani; Sergio Perticucci
Journal:  Gynecol Oncol       Date:  2003-08       Impact factor: 5.482

10.  Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.

Authors:  P H Sugarbaker; K A Jablonski
Journal:  Ann Surg       Date:  1995-02       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.